<IMS-DOCUMENT>0000092122-95-000092.txt : 19950815
<IMS-HEADER>0000092122-95-000092.hdr.sgml : 19950815
ACCESSION NUMBER:		0000092122-95-000092
CONFORMED SUBMISSION TYPE:	35-CERT
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		19950814
SROS:			NONE

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GEORGIA POWER CO
		CENTRAL INDEX KEY:			0000041091
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTRIC SERVICES [4911]
		IRS NUMBER:				580257110
		STATE OF INCORPORATION:			GA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		35-CERT
		SEC ACT:		1935 Act
		SEC FILE NUMBER:	070-08085
		FILM NUMBER:		95563703

	BUSINESS ADDRESS:	
		STREET 1:		333 PIEDMONT AVE NE
		CITY:			ATLANTA
		STATE:			GA
		ZIP:			30308
		BUSINESS PHONE:		4045266526
</IMS-HEADER>
<DOCUMENT>
<TYPE>35-CERT
<SEQUENCE>1
<DESCRIPTION>CERTIFICATE OF NOTIFICATION
<TEXT>

                          CERTIFICATE OF NOTIFICATION
                                    filed by
                             GEORGIA POWER COMPANY

         Pursuant to order of the Securities and Exchange Commission dated 
December 15, 1993, in the matter of File No. 70-8085.

         Georgia Power Company ("GEORGIA") hereby certifies to said Commission,
pursuant to Rule 24, that, in accordance with the terms and conditions of and
for the purposes represented by the statement on Form U-1, as amended, and of
said order with respect thereto the following information is provided.

1.       List of each Partnership Portfolio Company.

         (a)      AtheroGenics, Inc.
         (b)      Discovery Therapeutics, Inc.

2.       Fair Market Value of Partnership's Investment.

         $416,220.

3.       General description of the business activities of each such Partnership
         Portfolio Company.

         (a)      AtheroGenics, Inc. (a Georgia-based company) is engaged in the
         development of novel biopharmaceuticals and diagnostic markers which 
         address cardiovascular disease and its intervention.

         (b)      Discovery Therapeutics, Inc. (a Virginia-based company) is 
         engaged in the development of novel therapeutic products to treat 
         disorders and diseases related to the signal molecules dopamine and
         adenosine.

4.       Aggregate amount invested by GEORGIA in the Partnership during such 
         semi-annual period (January 1995 - June 1995).

         $750,000.

5.       GEORGIA's aggregate investment in the Partnership at end of June 30,
         1995.

         $1.5 million.

Dated:   August 14, 1995                    GEORGIA POWER COMPANY


                                            By:             Wayne Boston
                                            Wayne Boston, Assistant Secretary


</TEXT>
</DOCUMENT>
</IMS-DOCUMENT>
